Trials / Completed
CompletedNCT02444390
Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- UNICANCER · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective biomarker study to show that p4EBP1 staining predicts clinical benefit from treatment with everolimus in patients who are eligible for everolimus+exemestane treatment. This trial is not aimed at evaluating a drug activity. Everolimus and exemestane are prescribed within their approved indication as per usual practice and are not part of this trial.
Detailed description
Estrogen hormone receptor-positive metastatic breast cancer who failed to non steroidal aromatases inhibitors in patients who are eligible for everolimus+exemestane treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Biopsy | biopsy of a metastasis |
Timeline
- Start date
- 2015-05-19
- Primary completion
- 2018-10-01
- Completion
- 2022-07-01
- First posted
- 2015-05-14
- Last updated
- 2022-09-21
Locations
12 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02444390. Inclusion in this directory is not an endorsement.